Welcome to our dedicated page for Genprex SEC filings (Ticker: GNPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Genprex, Inc. filings document regulatory disclosures for a Nasdaq-listed clinical-stage gene therapy company with common stock traded on The Nasdaq Capital Market under GNPX. The company’s 8-K reports record material-event disclosures on Reqorsa patent grants and patent-application actions, research agreements, investor presentations, preclinical and clinical data presentations, diabetes gene therapy updates, and Nasdaq listing-compliance matters.
Proxy materials provide governance and compensation disclosures, including director and executive compensation tables, pay-versus-performance information and annual meeting matters. The filing record also ties Genprex’s capital-market status to its common stock listing, minimum stockholders’ equity compliance, and Regulation FD treatment for furnished presentation materials and press-release exhibits.
Genprex, Inc. is registering a shelf offering to sell up to $250,000,000 of securities, which may include common stock, preferred stock, warrants, debt securities, subscription rights and units, pursuant to a prospectus dated June 5, 2026.
The filing replaces a prior registration and includes $76,143,570.21 of unsold securities carried forward from the prior registration. The prospectus discloses a public float of $15,812,904 (based on 10,905,451 non-affiliate shares at $1.45) and states that net proceeds will be used for working capital and general corporate purposes.
Genprex, Inc. filed an 8-K to highlight new clinical data from an abstract presented at the 2026 ASCO Annual Meeting by its research collaborators. The work examined predictive biomarkers in lung cancer patients treated with its lead gene therapy candidate, Reqorsa (quaratusugene ozeplasmid).
The abstract reported that in Non-Small Cell Lung Cancer patients from Genprex’s Acclaim trials, Trop-2 H-scores above 100 and PTEN H-scores below 100 were associated with longer progression-free survival. In Small Cell Lung Cancer patients, Trop-2 levels were low and PTEN expression did not correlate with progression-free survival.
Genprex also found that NSCLCs with strong (3+) Trop-2 staining showed a near-significant relationship with progression-free survival, and plans to further study high Trop-2 expression as a potential biomarker for Reqorsa. The filing reiterates standard forward-looking statement cautions and related development and financing risks.
Genprex, Inc. reported that its research collaborators presented positive preclinical results for its diabetes gene therapy candidate PM (GPX-002) at the 2026 ASGCT Annual Meeting. In Type 2 diabetic mouse models on a high-fat diet, pancreatic delivery of AAV-Pdx1/MafA gene therapy reversed hyperglycemia and improved glucose-stimulated insulin secretion, indicating better β-cell function.
Electron microscopy showed more total and mature insulin granules and fewer immature granules after treatment, while transcriptomic analysis suggested β-cells shifted toward a more mature state. Genprex believes this preclinical work is a pivotal step toward a potentially transformative Type 2 diabetes treatment, with a technique the company views as technically translatable to humans.
Genprex, Inc. reported another quarterly loss as it advances its gene therapy pipeline for lung cancer and diabetes. For the three months ended March 31, 2026, the company generated no revenue and recorded a net loss of $4.46M as operating expenses rose to $4.49M.
Cash and cash equivalents increased to $18.05M, driven mainly by $13.36M of net proceeds from common stock sales under its at-the-market program, raising total stockholders’ equity to $16.93M. Shares outstanding grew sharply to 9,044,856 at March 31, 2026 and 10,586,402 as of May 11, 2026.
The company is enrolling patients in Phase 2 portions of its Acclaim-1 and Acclaim-3 REQORSA lung cancer trials, both benefiting from FDA Fast Track status, with Acclaim-3 also holding Orphan Drug Designation. Its GPX-002 diabetes gene therapy remains in preclinical development under expanded University of Pittsburgh licensing.
Management estimates existing cash will fund operations into the second half of 2027 but acknowledges recurring losses, lack of revenue, and dependence on future financings create substantial doubt about Genprex’s ability to continue as a going concern.
Ayrton Capital LLC, Alto Opportunity Master Fund (Segregated Master Portfolio B) and Waqas Khatri reported beneficial ownership of 249,788 shares of Genprex, Inc. Common Stock issuable upon exercise of warrants. The reported stake equals 2.69% of the class based on 9,044,856 shares outstanding as of March 27, 2026. The issuable shares are subject to a 9.99% beneficial ownership blocker. Holdings are reported "as of" March 31, 2026.
Genprex, Inc. announced that the Israel Patent Office has granted a patent covering the use of its REQORSA Gene Therapy (quaratusugene ozeplasmid) in combination with PD-1 antibodies for the treatment of cancer. This extends Genprex’s intellectual property around REQORSA beyond prior patents granted in the U.S., Japan, Mexico, Russia, Australia, Chile, China, Singapore and Europe.
REQORSA is initially being developed with approved cancer drugs to treat lung cancer, where preclinical studies have shown it can complement targeted drugs and immunotherapies. The company highlights Israeli public health data showing lung cancer is a leading cause of cancer deaths, underscoring the medical need in that market.
Genprex, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 18, 2026. Investors will elect two Class III directors, hold an advisory vote on 2025 executive pay, and ratify WithumSmith+Brown, PC as independent auditor for 2026.
Stockholders will also vote on an amended and restated 2018 Equity Incentive Plan and a reverse stock split of common stock at a ratio between 1-for-5 and 1-for-50, which the board could implement any time before December 31, 2027. An adjournment proposal would allow the meeting to be postponed to solicit more proxies if needed. Stockholders of record on April 24, 2026, when 10,417,400 shares were outstanding and entitled to vote, may participate virtually via proxydocs.com/GNPX.
Genprex, Inc. reported that its research collaborators will present positive preclinical data on its diabetes gene therapy candidate GPX-002 (Pdx1/MafA gene therapy) at the 2026 American Society of Gene and Cell Therapy Annual Meeting in Boston.
In Type 2 diabetic mouse models induced by a high fat diet, intrapancreatic delivery of an AAV-8 vector encoding Pdx1 and MafA reversed hyperglycemia and restored glucose-stimulated insulin secretion to levels similar to mice on a regular diet. Electron microscopy and transcriptomic analyses showed more mature insulin granules and a shift of β-cells toward a mature state after treatment. The company highlighted that direct pancreatic delivery via endoscopic retrograde cholangiopancreatography could make this approach technically translatable to humans, while emphasizing usual forward-looking statement cautions and development risks.
Genprex, Inc. filed a report describing a new Sponsored Research Agreement with The University of Texas MD Anderson Cancer Center to study biomarkers that may predict patient response to its Reqorsa Gene Therapy for non-small cell and small cell lung cancer.
The company also highlights progress in its Acclaim-1 and Acclaim-3 Phase 1/2 trials combining Reqorsa with Tagrisso and Tecentriq. Early Phase 1 data showed no dose limiting toxicities and signals of efficacy, including prolonged progression free survival and partial remissions in individual patients who continue on treatment.